12 Turkish soldiers die from methane gas in Iraqi cave while searching for remains of comrade killed by militants
Seven more Turkish soldiers have died from methane gas poisoning following a cave search operation in northern Iraq, Turkey's Defense Ministry said Monday, bringing the death toll to 12. The soldiers had been searching for the remains of a fellow soldier previously killed by Kurdish militants.
The troops were searching a mountain cave when 19 of them were exposed to the gas, according to the ministry. Five of the soldiers died Sunday from the colorless, odorless, flammable gas that can cause asphyxiation in sufficient concentration, and seven more succumbed on Monday.
"We pray for God's mercy upon our heroic martyrs who lost their lives in this tragic event," the ministry said Monday, also expressing hope for a rapid recovery for other troops that were affected.
It said Defense Minister Yasar Guler and armed forces' commanders were traveling to the region to carry out "inspections and evaluations" and attend funeral ceremonies.
The ministry said the incident took place in the "Claw-Lock Operation region" - a reference to an operation launched against the Kurdistan Workers' Party, or PKK, in northern Iraq in April 2022.
The ministry posted video on social media showing six of the dead soldiers being transported back to their hometowns.
Millî Savunma Bakanı Yaşar Güler'in beraberinde TSK Komuta Kademesi ile katıldığı Yüksekova Selahaddin Eyyübi Havalimanındaki törende, Pençe-Kilit Harekâtı bölgesinde şehit düşen altı kahraman silah arkadaşımızın naaşları defnedilmek üzere memleketlerine uğurlandı.… pic.twitter.com/rGXYcrdhP7 — T.C. Millî Savunma Bakanlığı (@tcsavunma) July 7, 2025
"The bodies of our six heroic comrades who were martyred in the Claw-Lock Operation region were sent to their hometowns for burial," the ministry wrote on X.
There was no immediate information on the condition of the seven other soldiers who were affected by the gas.
The did not explain the origin of the methane gas in the caves.
Turkey and the PKK have waged a 40-year conflict that has often spilled over into Iraq and Syria. Turkey has set up a series of bases in northern Iraq, where the PKK has been established for decades.
The PKK, which is considered a terrorist organization by Turkey and most of the West, announced in May that it would disband and renounce armed conflict as part of a new peace initiative with Turkey.
Its fighters are expected to begin handing over their weapons over the next few days in the first concrete move toward disarmament.
According to the ministry, the Turkish unit overcome by methane gas had been searching for the remains of an infantry officer killed by "terrorist gunfire" during a search-and-clear mission in May 2022. Recovery teams have been scouring the area for the past three years.
The cave where the incident occurred sits at an altitude of 2,795 feet and had previously been used by the PKK as a field hospital.
News of the soldiers' deaths emerged as a delegation from the pro-Kurdish DEM party was visiting jailed PKK founder Abdullah Ocalan as part of the ongoing negotiations with the Turkish government.
Agence France-Presse contributed to this report.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 days ago
- Forbes
Turkey Legalizes Medical Cannabis Sales In Pharmacies
A technician inspects the leaves of cannabis plants growing inside a controlled environment in North ... More Macedonia. Photographer: Konstantinos Tsakalidis/Bloomberg Turkey has passed a landmark bill that legalizes the sale of cannabis products for medical use in pharmacies, marking a step forward in expanding patient access to such treatment. The Turkish Parliament this week approved a bill that allows the sale of cannabis-based products in pharmacies with a prescription. The bill, introduced by the Justice and Development Party (AK Party), led by President Recep Tayyip Erdoğan, published in the Official Gazette yesterday, regulates access to medical cannabis products that are non-intoxicating and low in THC, such as those containing CBD. It amended a number of laws, including the narcotics law and regulations related to pharmacies and shops that sell poisonous or effective chemical substances. These regulations reportedly aim to meet healthcare needs through domestic production, reduce dependence on imports, and prevent the use of unregistered products. The changes, therefore, are expected to boost the legal production of low-THC medical cannabis in Turkey. Under the new rules, the cultivation of medical cannabis will be supervised by the Ministry of Agriculture and Forestry, while processing, export, licensing, registration, and authorization for sale will fall under the oversight of the Ministry of Health. By amending the narcotics law, medical cannabis products will now be available through pharmacies. Furthermore, each product will be tracked from production or import all the way to patient use through a centralized tracking system designed to block counterfeit, smuggled, or unauthorized products from entering the legal market. The law limits medical cannabis sales to pharmacies in order to block access through unregulated retail and online markets, with the aim to protect public health and ensure product safety. Concerns Over Medical Cannabis Bill Before the bill became law, the Turkish Medical Association (TTB) criticized the proposed cannabis regulation, arguing that there is not enough scientific evidence to support the medical benefits of cannabis and warned that its widespread use could lead to serious physical and mental health risks. In December 2020, the UN Commission on Narcotic Drugs (CND), the United Nations' drug policy-making body, reclassified cannabis and cannabis resin under an international category that acknowledges their medical value. The association also urged lawmakers to remove the cannabis-related measures from the bill, which has also faced criticism from members of some opposition parties. While the new law will allow people to purchase low-THC medical cannabis products from pharmacies, easing access for treatment, cannabis remains illegal in Turkey for recreational use. In 2016, legislation allowed the use of sublingual cannabinoid medications, such as Sativex, with a doctor's prescription. The new law, however, is expected to make it easier for medical cannabis patients to obtain cannabis products from pharmacies with a prescription. This reform is also viewed as a significant step toward supporting Turkey's entry into the cannabis-based product market and boosting its international competitiveness. Turkey is, in fact, not new to cannabis cultivation, particularly hemp, which is legal in several provinces for medical and scientific purposes. According to data from TurkStat, compiled by the state-run Anadolu news agency, Turkey's cannabis seed production surged about 70% year-on-year in 2024, reaching 556 tons, up from 273 tons in 2020. Turkey now joins other European countries where medical cannabis is legal, such as Italy and Germany, which, however, allow products with higher levels of THC. Ukraine has also recently legalized medical cannabis.
Washington Post
2 days ago
- Washington Post
What to know about weighted vests
For years, the military and law enforcement have used weighted vests for conditioning. Today, thanks in part to social media, more regular folks are strapping them on to get more out of their workouts. Adding a weight-bearing element to your workout can help build bone density, increase functional strength and improve balance. But weighted vests aren't for everyone, and wearing one that doesn't fit right or is too heavy can cause problems. Before you slip one on, there are things to consider.
Medscape
3 days ago
- Medscape
A Puzzling Pneumothorax in a 36-Year-Old Woman
A 36-year-old woman with no significant medical history presented with recurrent spontaneous pneumothorax accompanied by acute chest pain and shortness of breath, an unusual occurrence, particularly in non-smokers without underlying lung disease. The case was reported by Farman H. Fatah, MD, and colleagues from the University of Sulaymaniyah, Sulaymaniyah, Iraq. The Patient and Her History The patient presented to the emergency department with acute left-sided chest pain and shortness of breath. She had a history of asthma and right-sided spontaneous pneumothorax 7 years earlier, which was treated with video-assisted thoracoscopic surgery (VATS) and pleurodesis. Her family history was notable for asthma on her mother's side and colonic cancer on her father's side. She denied any history of smoking or environmental exposures. On physical examination, breath sounds were markedly decreased over the left hemithorax. A chest x-ray was performed, revealing a left-sided apical pneumothorax characterised by a region of radiolucency with absent lung markings, indicating air accumulation in the pleural space. A pigtail catheter was inserted to relieve the pneumothorax. Despite appropriate pigtail placement and conservative management, the pneumothorax persisted. The patient was referred for surgical evaluation and underwent VATS with pleurodesis and wedge resection. Intraoperatively, a ruptured subpleural bleb in the left upper lobe was identified and excised. Histopathology of the resected tissue was non-specific and showed no malignancy. A chest CT was performed to investigate the underlying cause. Imaging revealed the site of the bleb rupture and multiple thin-walled cysts scattered throughout the lung parenchyma. Given the history of recurrent spontaneous pneumothorax, presence of bilateral pulmonary cysts, and family history of cancer, Birt-Hogg-Dubé syndrome (BHDS) was suspected. Findings and Diagnosis Genetic testing for mutations in the FLCN gene confirmed the diagnosis. The test included sequencing and deletion/duplication analyses of FLCN . A pathogenic mutation in FLCN , confirmed by molecular testing, established a diagnosis of BHDS. BDHS is a rare autosomal dominant disorder caused by mutations in the FLCN gene and is characterised by a clinical triad of pulmonary cysts with spontaneous pneumothorax, cutaneous fibrofolliculomas, and renal tumours. Although the estimated prevalence of BHDS is approximately two cases per million, its actual incidence is believed to be higher due to frequent underdiagnosis and highly variable clinical presentations, even among members of the same family. BHDS is often suspected in patients presenting with cystic lung lesions, a family history of related manifestations, recurrent pneumothorax, and characteristic dermatologic findings. A definitive diagnosis is established through genetic testing to confirm pathogenic variants in the FLCN gene. The patient had no known renal or dermatologic manifestations at the time of diagnosis of the disease. She continued to experience mild postoperative dyspnoea and chest discomfort but resumed her daily activities and returned to work. She was scheduled for routine follow-up, including pulmonary function testing and renal surveillance imaging, according to the BHDS management guidelines. Discussion Pulmonary manifestations are often the earliest and most prominent clinical features of BHDS, frequently preceding skin and renal findings. The syndrome is characterised by multiple bilateral pulmonary cysts that tend to be irregular, thin-walled, and predominantly located in the basal and subpleural regions of the lungs. These cysts predispose affected individuals to spontaneous pneumothorax, which can be the first and sometimes the only presenting symptom. One of the key challenges in diagnosing BHDS is its variable presentations. While the classical triad includes skin fibrofolliculomas, renal tumours, and pulmonary cysts, some individuals, like our patient, may present solely with pulmonary involvement. This phenotypic variability can lead to delayed or missed diagnoses, particularly when cutaneous or renal signs are absent or subtle. Approximately 41% of pulmonary cysts present with spontaneous pneumothorax, with a recurrence rate of 41%. The majority of patients (> 90%) develop multiple fibrofolliculomas, especially on the face and upper trunk, in the second or third decade of life, with dermatologic findings serving as the first clinical clue in 25%-50% of cases. Renal tumours are observed in nearly 30% of patients, at a mean age of 50 years. Although the estimated prevalence of BHDS is approximately two cases per million, its actual incidence is believed to be higher due to frequent underdiagnosis and highly variable clinical presentations, even among members of the same family. This highlights the importance of considering BHDS in the differential diagnosis of spontaneous pneumothorax, particularly when it is recurrent or associated with atypical cystic lung disease. Genetic confirmation through FLCN mutation testing is crucial not only to establish a definitive diagnosis but also to initiate appropriate long-term surveillance for potentially life-threatening renal malignancies. Surgical intervention, such as VATS pleurodesis, may be necessary when conservative approaches fail. This case underscores the importance of considering BHDS in patients presenting with recurrent spontaneous pneumothorax, particularly when bilateral pulmonary cysts are evident and no other clear aetiology is identified.
